Compare AbCellera Biologics Inc (ABCL) vs Marathon Digital Holdings Inc (MARA) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

MARA Holdings trades at $12.95, up 4.44% today, but faces significant fundamental challenges with a net income margin of -234.83% and three consecutive quarterly earnings misses. The technical picture remains bearish with key resistance at $13-$14, while analyst sentiment is mixed with a 50% buy rating but a consensus price target of $16.60. Recent developments include the shipment of a hybrid energy storage prototype system from TAE Power Solutions (PRNewsWire, June 30, 2026) and ongoing pivot toward AI infrastructure.

Despite the bullish analyst consensus and potential from AI infrastructure expansion, MARA faces substantial execution risks amid persistent losses and negative cash flow from operations. The stock's valuation appears attractive on P/E (3.37) and EV/EBITDA (3.31) metrics, but profitability concerns and Bitcoin market volatility create significant downside risk for investors.